From Ozempic to BPC-157, graded on the evidence
48 peptides, approved or not, with their risks, what users report and the law where you live. Nothing here is for sale.
FilterEverything
Body part
Whole-body effect
All peptides
Sort by
SemaglutideWeight loss in obesity +5 moreProvenPrescriptionVery highWikipedia attention: Very high. Falling. Data through Sep 2026TirzepatideWeight loss in obesity +5 moreProvenPrescriptionVery highWikipedia attention: Very high. Steady. Data through Sep 2026BremelanotideLow sexual desire in premenopausal women +1 moreProvenPrescriptionModerateWikipedia attention: Moderate. Falling. Data through Sep 2026LiraglutideWeight loss in obesity +2 moreProvenPrescriptionModerateWikipedia attention: Moderate. Steady. Data through Sep 2026OrforglipronNot a peptide, newWeight loss in obesity +1 moreProvenPrescriptionModerateWikipedia attention: Moderate. Falling. Data through Sep 2026TesamorelinBelly fat in HIV-related lipodystrophy +2 moreProvenPrescriptionModerateWikipedia attention: Moderate. Steady. Data through Sep 2026AfamelanotideSun tolerance in erythropoietic protoporphyriaProvenPrescriptionLowWikipedia attention: Low. Steady. Data through Sep 2026ElamipretideMuscle strength in Barth syndrome +3 moreProvenPrescriptionLowWikipedia attention: Low. Falling. Data through Sep 2026EnlicitideNewHigh LDL cholesterolProvenPrescriptionLowWikipedia attention: Low. Insufficient history. Data through Sep 2026IcotrokinraNewModerate-to-severe plaque psoriasis +1 moreProvenPrescriptionLowWikipedia attention: Low. Rising. Data through Sep 2026LinaclotideIrritable bowel syndrome with constipation +1 moreProvenPrescriptionLowWikipedia attention: Low. Steady. Data through Sep 2026TeriparatideOsteoporosis at high risk of fractureProvenPrescriptionLowWikipedia attention: Low. Steady. Data through Sep 2026AbaloparatideOsteoporosis at high risk of fractureProvenPrescriptionVery lowWikipedia attention: Very low. Steady. Data through Sep 2026RusfertideNewPolycythemia vera (excess red blood cells)ProvenPrescriptionVery lowWikipedia attention: Very low. Rising. Data through Sep 2026SetmelanotideObesity from rare genetic causes +1 moreProvenPrescriptionVery lowWikipedia attention: Very low. Steady. Data through Sep 2026RetatrutideUpcomingWeight loss in obesity +3 moreSupportedTrials onlyVery highWikipedia attention: Very high. Falling. Data through Sep 2026CagriSemaUpcomingWeight loss in obesity +1 moreSupportedUnder reviewModerateWikipedia attention: Moderate. Steady. Data through Sep 2026AmycretinUpcomingWeight lossSupportedTrials onlyVery lowWikipedia attention: Very low. Falling. Data through Sep 2026EloralintideUpcomingWeight loss in obesitySupportedTrials onlyVery lowWikipedia attention: Very low. Insufficient history. Data through Sep 2026MariTideAntibody conjugate, upcomingWeight loss in obesitySupportedTrials onlyVery lowWikipedia attention: Very low. Falling. Data through Sep 2026MazdutideUpcomingWeight loss and type 2 diabetesSupportedTrials onlyVery lowWikipedia attention: Very low. Falling. Data through Sep 2026PemvidutideUpcomingFatty liver disease (MASH) +1 moreSupportedTrials onlyVery lowWikipedia attention: Very low. Falling. Data through Sep 2026PetrelintideUpcomingWeight loss in obesitySupportedTrials onlyVery lowWikipedia attention: Very low. Falling. Data through Sep 2026SurvodutideUpcomingWeight loss in obesity +1 moreSupportedTrials onlyVery lowWikipedia attention: Very low. Falling. Data through Sep 2026GHK-CuWrinkles and firmness (cream or serum) +3 moreEarlyNo prescriptionHighWikipedia attention: High. Falling. Data through Sep 2026Melanotan IITanning +2 moreEarlyRules in fluxModerateWikipedia attention: Moderate. Falling. Data through Sep 2026SelankAnxiety +1 moreEarlyNot approvedModerateWikipedia attention: Moderate. Falling. Data through Sep 2026SermorelinMuscle and body fat in adults +2 moreEarlyCompounded onlyModerateWikipedia attention: Moderate. Falling. Data through Sep 2026DSIPInsomniaEarlyNot approvedLowWikipedia attention: Low. Falling. Data through Sep 2026KisspeptinTriggering egg maturation in IVF +3 moreEarlyNot approvedLowWikipedia attention: Low. Falling. Data through Sep 2026Matrixyl and ArgirelineFine lines and wrinklesEarlyNo prescriptionLowWikipedia attention: Low. Steady. Data through Sep 2026Collagen peptidesSkin hydration and elasticity +2 moreEarlyNo prescriptionNot measuredWikipedia attention: Not measuredBPC-157Tendon, ligament and muscle injuries +3 moreLab onlyRules in fluxHighWikipedia attention: High. Falling. Data through Sep 2026CJC-1295Muscle gain, fat loss, anti-aging +1 moreLab onlyNot approvedModerateWikipedia attention: Moderate. Falling. Data through Sep 2026IpamorelinMuscle gain, fat loss, anti-aging +3 moreLab onlyNot approvedModerateWikipedia attention: Moderate. Falling. Data through Sep 2026SemaxFocus and memory in healthy people +2 moreLab onlyRules in fluxModerateWikipedia attention: Moderate. Falling. Data through Sep 2026TB-500Injury recovery +2 moreLab onlyRules in fluxModerateWikipedia attention: Moderate. Falling. Data through Sep 2026DihexaMemory and learningLab onlyRules in fluxLowWikipedia attention: Low. Falling. Data through Sep 2026EpitalonLonger telomeres and longer life +2 moreLab onlyRules in fluxLowWikipedia attention: Low. Falling. Data through Sep 2026MOTS-cSlowing aging, more energy +2 moreLab onlyRules in fluxLowWikipedia attention: Low. Falling. Data through Sep 2026GHRP-2 and GHRP-6Muscle gain or anti-aging +2 moreLab onlyNot approvedVery lowWikipedia attention: Very low. Falling. Data through Sep 2026HumaninSlowing aging +1 moreLab onlyNot approvedVery lowWikipedia attention: Very low. Steady. Data through Sep 2026LL-37Fighting infections +1 moreLab onlyRules in fluxVery lowWikipedia attention: Very low. Falling. Data through Sep 2026Thymosin alpha-1General immune boosting in healthy people +3 moreLab onlyNot approvedVery lowWikipedia attention: Very low. Falling. Data through Sep 2026KPVInflamed bowel +1 moreLab onlyRules in fluxNot measuredWikipedia attention: Not measuredCerebrolysinAcute stroke +2 moreFailedNot approvedLowWikipedia attention: Low. Falling. Data through Sep 2026AOD-9604Fat lossFailedNot approvedVery lowWikipedia attention: Very low. Falling. Data through Sep 2026LarazotideCeliac symptoms despite a gluten-free diet +1 moreFailedNot approvedVery lowWikipedia attention: Very low. Steady. Data through Sep 2026